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effectiveness results. The objective of this study was to determine
whether there was a relationship between the source of funding
and the reporting of positive results. METHODS: We conducted
a systematic review of the literature to identify economic evalu-
ations of bisphosphonates for the treatment of osteoporosis. We
extracted the source of funding, region of study, the journal name
and impact factor and all reported incremental cost effectiveness
ratios (ICERs). We identiﬁed which ICERs were under the thresh-
olds of $20,000, $50,000 and $100,000 A quality score between
0 and 7 was also given to each of the studies. We used generalized
estimating equations (GEE) for the analysis. RESULTS: The sys-
tematic review yielded 532 potential abstracts: Seventeen met our
ﬁnal eligibility criteria, 531 ICERs were analyzed, and ten studies
(59%) were funded by industry. There was no signiﬁcant differ-
ence between industry and non-industry funded studies reporting
ICERs below the thresholds of $20,000 and $50,000. However
industry sponsored studies were more likely to report ICERs
below $100,000 [OR = 4.69, 95%CI (1.77–12.43)]. Studies of
higher methodological quality (higher than 4.5) were less likely
to report ICERs below $20,000 and $50,000 than studies of
lower methodological quality (score under 4). Methodological
quality was not signiﬁcantly different between studies reporting
ICERs under $100,000. CONCLUSIONS: Our study shows that
funding source (industry vs. non-industry) did not signiﬁcantly
affect the reporting of ICERs below $20,000 and $50,000 thresh-
olds. Methodological quality might be a more signiﬁcant factor
than source of funding in differentiating which studies are likely
to report favorable ICERs, with the higher quality studies sig-
niﬁcantly less likely to report ICERs below $20,000/QALY and
$50,000/QALY.
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OBJECTIVE: To determine the annual drug and administration
costs and dosage patterns for patients with rheumatoid arthritis
(RA) treated with inﬂiximab or abatacept from a managed
care perspective. METHODS: A retrospective analysis of medical
claims was performed using the PharMetrics claims database.
Patients with RA were identiﬁed from Janaury 1, 2003-
December 31, 2005 for those prescribed inﬂiximab and February
1, 2006-December 31, 2006 for those prescribed abatacept as
ﬁrst or subsequent biologic treatment. Patients were followed
until medication switch, discontinuation, or end of study period.
Primary outcomes of interest were annual drug and administra-
tion costs and dose escalation (increase in dose, dosing frequency
or both). Patients’ weight information required to calculate dose
were unavailable, therefore paid amounts were used as proxy for
dose. RESULTS: From ﬁrst to last infusion, patients receiving
inﬂiximab (n = 1913) as ﬁrst or subsequent biologic experienced
an average dose increase of 17% and 39%, respectively. A
total of 58% and 73% patients prescribed inﬂiximab as ﬁrst
or second-plus biologic experienced dose escalation, respectively.
For patients receiving abatacept (n = 184) as ﬁrst or subsequent
biologic, dose increase averaged 1.2% and 6.5%, respectively
(no increase in number of vials for either). The dosing interval for
patients receiving abatacept followed the recommended dosing
regimen. Patients treated with inﬂiximab experienced an increase
in dosing frequency, averaging 49 days earlier in treatment (from
4th to 14th infusion) and 33 days later in treatment (15th to last
infusion). The estimated annual drug plus infusion administra-
tion cost of ﬁrst and subsequent biologic therapy was $13,354
and $14,465 for abatacept and $16,608 and $23,913 for inﬂix-
imab, respectively. CONCLUSION: Patients treated with inﬂix-
imab experienced an increase in dosage and/or dosing frequency,
resulting in an increase in real world treatment costs. Patients
treated with abatacept showed no considerable increase in dose
or dosing frequency from ﬁrst to last infusion.
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OBJECTIVE: To evaluate the cost-effectiveness of etoricoxib
(90 mg), celecoxib (200/400 mg), and the non-selective NSAIDs
naproxen (1000 mg) and diclofenac (150 mg) in the initial treat-
ment of ankylosing spondylitis (AS) in the UK. METHODS: A
Bayesian cost-effectiveness model was developed to estimate the
costs and beneﬁts associated with initiating AS treatment with
etoricoxib, celecoxib, diclofenac, or naproxen. Efﬁcacy, safety
and medical resource and cost data were obtained from the
literature. With mixed treatment comparison meta-analysis the
obtained efﬁcacy estimates were synthesized. Treatment beneﬁt
and degree of disease activity, as reﬂected with BASFI and
BASDAI scores, were related to quality adjusted life years
(QALYs) and disability related costs. Other cost outcomes
related to drug acquisition, gastrointestinal and cardiovascular
safety were taken into consideration. Uncertainty in the source
data was translated into uncertainty in cost-effectiveness esti-
mates and therefore decision uncertainty. RESULTS: There was
more than 98% a probability that etoricoxib results in greater
QALYs than the other interventions. Over a 30-year time
horizon, etoricoxib is associated with about 0.5 more QALYs
than the other interventions. At 2 years there is a 77% probabil-
ity that etoricoxib shows the lowest cost. This increases to >99%
at 30 years. At 30 years etoricoxib is expected to save 19,460
relative to celecoxib (200/400 mg) and 14,140 relative to
naproxen and diclofenac. For a willingness-to-pay ceiling ratio of
20,000 per QALY there is a >97% probability that etoricoxib
is the most-cost-effective treatment. Additional analysis with
different assumptions, including celecoxib 200 mg, and ignoring
cost-offsets associated with AS disability, supported these ﬁnd-
ings. CONCLUSION: This economic evaluation demonstrated
that etoricoxib is the most cost-effective NSAID treatment for AS
patients in the UK.
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OBJECTIVE: Chronic pain conditions, such as osteoarthritis
(OA) and mechanical chronic low back pain (CLBP), among
active workers cost employers ~$61.2 billion/yr in lost produc-
tive time, which includes both reduced performance while at
work and days of work missed (absenteeism). An analysis of lost
productivity time from a 56-week, open-label study was con-
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ducted to calculate the potential economic effects of treatment
with HC/APAP CR to employers. METHODS: As part of a
larger clinical trial reported elsewhere, the Work Productivity
and Activity Impairment (WPAI) instrument was administered at
baseline and weeks 24 and 56 to measure reduced productivity
and overall work impairment due to health. Results are reported
as percentage of lost productivity time and estimated economic
impact to employers. Using the 2006 U.S. average weekly wage
of $861, the mean costs of reduced productivity and overall work
impairment due to health were calculated. The economic impact
of improved work productivity and overall work impairment due
to health after treatment with HC/APAP CR was calculated as
the difference in cost from baseline to week 24 and week 56.
RESULTS: Impairment while working due to health decreased
from baseline by 17.4% at week 24 and 16.6% at week 56.
This translates into an estimated cost-savings (per employee) to
employers of $3527 at week 24, and $8019 at week 56. Similarly,
overall work impairment due to health decreased from baseline
by 17.5% at week 24 and 15.8% at week 56. This translates into
an average potential savings to employers of $3614 at week 24
and $7596 at week 56. Absenteeism decreased by 1.1% at week
24 and by 0.04% at week 56. CONCLUSION: As assessed
by WPAI instrument, this subanalysis demonstrated 12-hour,
extended-release HC/APAP CR improved work productivity
after 24 and 56 weeks of treatment in patients with OA and
CLBP.
MUSCULAR-SKELETAL DISORDERS—
Patient-Reported Outcomes
PMS31
TWO-YEAR LONGITUDINAL STUDY OF PERSISTENCETO
ANTI-TUMOR NECROSIS FACTORTREATMENT AMONG
RHEUMATOID ARTHRITIS PATIENTS
Tang B1, Rahman MI1, Naim A1, Changolkar A2
1Centocor, Inc, Horsham, PA, USA, 2SOAL PharmaTech Solutions,
LLC, Philadelphia, PA, USA
OBJECTIVE: To evaluate long-term persistence of anti-
TNF treatment among rheumatoid arthritis (RA) patients.
METHODS: A retrospective study utilizing managed-care claims
from the PharMetrics database was conducted. The ﬁrst anti-
TNF (inﬂiximab, etanercept, or adalimumab) encounter (index
biologic date) among RA patients between January 1, 2000 and
January 1, 2006 was identiﬁed. Patients were required to have a
minimum of 30-months of continuous plan eligibility; 6 months
prior to and 24 months following their index biologic date, as
patients were followed-up for 24 months after the index biologic
date. Anti-TNF persistence was deﬁned as the number of days
between ﬁrst biologic prescription and their last biologic encoun-
ter, and the persistence rate was deﬁned as the persistence days
divided by 730 and multiplied by 100. Univariate and multivari-
ate analyses were applied to determine if differences in per-
sistence existed among three cohorts: patients who received
methotrexate (MTX) and combined with inﬂiximab; etanercept;
and adalimumab. RESULTS: A total of 2155 patients were ana-
lyzed consisting of 605 (28.1%) in inﬂiximab group; 1,121
(52.0%) in etanercept group; and 429 (19.9%) in adalimumab
group, over two-thirds (75%) were female and the mean age
was 49.5 years. Age, gender, Charlson Co-morbidity Index and
disease staging were similar among three cohorts. The overall
persistence with anti-TNF agents was 535.7 days in the two-year
follow-up period (73.4%). The inﬂiximab cohort was more per-
sistent (580.1 days, 79.5%) than the other 2 cohorts (etanercept
group 520.3 days, 71.3%); and adalimumab group 513.3
days, 70.3%) and was statistically signiﬁcant (p < 0.0001). After
controlling for demographic variables and disease severity, dif-
ferences among the three cohorts were statistically signiﬁcant
(p < 0.0001). CONCLUSION: These results indicate that
patients on inﬂiximab plus MTX are more persistent with anti-
TNF therapy than other anti-TNF cohorts. Further studies are
needed to evaluate the impact of persistence on economic, clini-
cal, and humanistic outcomes.
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OBJECTIVE: The primary purpose of this study was to evaluate
the relationship between compliance to rheumatoid arthritis
(RA) specialty medications and the total health care (pharmacy
and medical) costs among RA patients. METHODS: Deidentiﬁed
pharmacy claims and medical claims data from a large pharmacy
beneﬁt manager’s database were used in this retrospective study.
Members who were primarily diagnosed with RA (ICD-9 714.0)
and who have had at least one prescription for specialty medi-
cations between July-December 2005 were identiﬁed for the
analysis. Specialty medications included for this study were as
follows: Enbrel, Humira, Kineret, Remidace, Orencia, Rituxan.
Members’ pharmacy and medical claims in 2006 were collected
to measure their compliance and total health care cost. Member’s
compliance to specialty medications was assessed by Medication
Possession Ratio (MPR). Members were categorized into three
different groups as—compliant (MPR > 0.8), partially compliant
(MPR 0.5–0.8), and non-compliant (MPR < 0.5). All pharmacy
costs; all medical costs and their breakdown cost such as physi-
cian visit, hospitalization, and ER visit etc; as well as total health
care costs were computed and compared across the three groups
using independent t-tests. RESULTS: A total of 689 members
were diagnosed as RA, but only 148 members using specialty RA
medications were included for the analysis. Compliant group
members had signiﬁcantly high pharmacy cost ($19,615 vs.
$10,050) and signiﬁcantly low medical cost ($3041 vs. $9086 )
as compared to the non-compliant groups (P < 0.01). Compliant
group members showed signiﬁcant low physician visit cost
($1,451 vs. $2,386 P < 0.01) and hospitalization cost compared
to non-compliant group ($236 vs. $3,206 P < 0.05). The total
health care costs were found to be comparable and non-
signiﬁcant among the three groups. CONCLUSION: The study
demonstrated patients with good compliance tend to have higher
pharmacy cost and lower medical costs as compared to those
non-compliant to their therapy.
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OBJECTIVE: The consequences of patient non-compliance have
been well documented in the literature and have been associated
with poor health conditions and increased health care costs.
Several studies have shown that the overall health care costs
were lower for compliant patients than for non-compliant
patients despite an increase in the pharmaceutical costs.
Although, plenty research has been done describing the relation-
ship between compliance and total health care costs, none has
been conducted on specialty medications that are used to treat
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